EUVIMEDEUVIMED entdecken
Crossref

Real‐world predictors of dupilumab prescription in patients with chronic rhinosinusitis with nasal polyps

Christina Dorismond iD, Mason R Krysinski, Yash Trivedi, Rory J Lubner iD, Rakesh K Chandra, Naweed I Chowdhury, Justin H Turner

International Forum of Allergy & Rhinology · 2025

DOI: 10.1002/alr.23483 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Forum of Allergy & Rhinology, 2025. Verfasst von Christina Dorismond und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Nasal Polyps, Sinusitis, Antibodies, Monoclonal, Humanized, Rhinitis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: NIAID NIH HHS, NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite increasing dupilumab use for chronic rhinosinusitis with nasal polyps (CRSwNP), little is known about the factors influencing its use in real‐world practice. We aimed to identify factors that may predict dupilumab prescription in CRSwNP patients who have undergone endoscopic sinus surgery (ESS).

Methods

A single‐institution, retrospective cohort study of patients who underwent ESS for CRSwNP between 2015 and 2023 was conducted. Demographics, comorbidities, 22‐item sinonasal outcome test (SNOT‐22) scores, and dupilumab prescription date were extracted from patient records. Intraoperative nasal mucus cytokine levels were measured using a multiplex bead assay. Univariate logistic regression analysis was performed to identify factors associated with dupilumab prescription, and multivariate logistic regression was used to adjust for surgery date.

Results

A total of 299 CRSwNP patients were included, including seventy (23.4%) who were prescribed dupilumab postoperatively. Patients were more likely to be prescribed dupilumab if they had asthma (odds ratio [OR] 2.304), aspirin‐exacerbated respiratory disease (AERD, OR 3.375), elevated tissue eosinophils (OR 1.005), and higher 3‐month postoperative SNOT‐22 scores (OR 1.027). Patients prescribed dupilumab also had greater odds of having elevated mucus interleukin (IL)‐5 (OR 1.128) and IL‐13 (OR 1.213). When adjusting for surgery date, associated factors included: asthma (OR 2.444), AERD (OR 3.750), allergic rhinitis (OR 1.833), higher tissue eosinophils (OR 1.005), elevated 3‐month SNOT‐22 scores (OR 1.028), and higher IL‐5 (OR 1.123) and IL‐13 (OR 1.202) levels.

Conclusion

Asthma, AERD, allergic rhinitis, and elevated tissue eosinophil, IL‐5, and IL‐13 levels are predictive of dupilumab prescription in CRSwNP patients. These may serve as clinical and inflammatory biomarkers and can aid in counseling patients about expected disease trajectory.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasal PolypsSinusitisAntibodies, Monoclonal, HumanizedRhinitisHumansMaleFemaleMiddle AgedChronic DiseaseRetrospective StudiesAdultAgedCytokinesEndoscopyRhinosinusitis

Stichwörter der Autor:innen

Dupixentchronic rhinosinusitiscytokinedupilumabnasal polyppolyposispredictors

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedCytokines

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Otolaryngology-Head and Neck Surgery, University of Alabama-Birmingham, Birmingham, Alabama, USA.

ORCID-Profile: Christina Dorismond, Rory J Lubner

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • NIA NIH HHS
  • NCATS NIH HHS
  • National Institutes of Health
  • National Center for Advancing Translational Sciences

Zitieren

APA

Dorismond, C., Krysinski, M. R., Trivedi, Y., Lubner, R. J., Chandra, R. K., Chowdhury, N. I., & Turner, J. H. (2025). Real‐world predictors of dupilumab prescription in patients with chronic rhinosinusitis with nasal polyps. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23483

Vancouver

Dorismond C, Krysinski MR, Trivedi Y, Lubner RJ, Chandra RK, Chowdhury NI, et al. Real‐world predictors of dupilumab prescription in patients with chronic rhinosinusitis with nasal polyps. International Forum of Allergy & Rhinology. 2025. doi:10.1002/alr.23483

BibTeX
@article{Dorismond2025,
  author = {Dorismond, Christina and Krysinski, Mason R and Trivedi, Yash and Lubner, Rory J and Chandra, Rakesh K and Chowdhury, Naweed I and Turner, Justin H},
  title = {Real‐world predictors of dupilumab prescription in patients with chronic rhinosinusitis with nasal polyps},
  journal = {International Forum of Allergy & Rhinology},
  year = {2025},
  doi = {10.1002/alr.23483}
}
Kostenlos starten →